Yes. Every idiot only bought at .17 and none at all the other really cheapies the other idiots mentioned when it was over a buck, last chance at 2, last chance at .90, etc. You'll be able to buy at .17 again soon. As I've said before, I made money on this P&D when the P still worked. It doesn't anymore. So I've made money literally everywhere else. But opportunity costs isn't even in all these brilliant long investor's vocabularies.

I'm not angry at all because I make money in the stock market by not betting on lottery ticket turds.

This is not a cheerleader/bot/shill board despite your wishes. It's to discuss a slimy company and their stock.

SO you say there are a billion shares short. And you say they've released a series of game changing news. Yet no short squeeze.

You aren't as smart as you think you are.

Less told you nothing is happening til the fall. MHRA takes 300+ days to make decisions regardless of their 150 policy. They told you Flaskworks is a long way from commercial production viability (not that there will ever be anything to produce anyway). Malik didn't think the value of what he had was going up anytime soon. The company doesn't think there is a chance of approval with the FDA, thus they haven't even filed the BLA.

How many more signals do you need that this will keep going down?

And they're even cheaper today. And every day til they are worthless.

The saying is "a fool and his money are easily parted". This board has considered "cheapies" anything under $7 back when the OS was not 1.3 billion. And those who have "bought cheapies" when this board says so are buried in red. Buying cheapies is great for stocks going up. But I don't think you understand the stock market. Or scam companies like this.

Your shares are as valuable as the other 1.3 billion $0.32 shares.

Keep buying cheapies. A fool and his money......

Are you saying many of those credited in the paper are fully onboard with DCVax and nothing else?

Some of the contributors also contributed to the Optune trial publication that led to the approval. Many recommend many of the other treatments.

Hell, Dr. Khagi (a contributor of the DCVax paper) recommends Optune to many of his patients and created a video for it:

Literally one of my first searches

His expertise

Cool. Maybe in 5 years they can get to the comparability study.

Most companies with one languishing expensive placeboesque product can't keep their shareprice over $1. Ask NWBO since they've R/Sed twice and still have a billion and a half OS.

Quote the guy who has been wrong since 8/24/2015.

Woohooo. More endless cheapies!

Feel free to post your brilliant trades. Anyone had a chance to buy cheapies at 5,7,9 dollars too. And since the whole board of shills said this was going to $25, why would anyone sell at $2? What were your SP predictions since 2015? I’ll bet a bit more than $2.

Your son is right.

It won’t replace SOC as it was never tested as a monotherapy.
Moot point as it doesn’t work anyway with or without chemorad.

Nobody is suffocating the company. LPs goal has nothing to do with cancer patients and everything to do with building and selling Advent.

You had it once and only once and screwed the guy over.

Given their website is barely updated since 2003, are they talking about Cognate, or Advent?

And shouldn't it be "My CDMO"?

They probably died of old age.

Shot on Betamax.

It didn't. Opened at 1.39 Thursday, closed at 1.21. Pump PR Friday morning to open at 1.63 and close at 1.31. So it gained 9%, not 50%.

Classic P&D. It helps that OS is low because of their last R/S.

CVM is LP's role model. Don't admit the futility rec until years later. Live on shitty data. Fool shareholders. CVMs CEO probably is jealous of LP's building and selling CDMO hustle.

It’s over 100% profit since all you guys lie about buying at .17. Not the cheapies at 2,3,4,10 dollars. Is it 2 billion OS yet?

Yeah she’s trailblazing trying to get approval in irrelevant UK because she already knows the redone trial has zero chance for FDA approval. She knows there’s zero chance for MHRA approval too but it gave her over a year to kick the can down the road to finance Advent. Then she’ll reboot zero ORR Direct to buy more time. She knew the rejection would take over a year while you guys were saying approval in 120 days.

Stupp is more well respected AND the company paid him and he still can’t say anything good about the crappy trial’s data.

They've already done it right once. LP let shareholders build her a nice CDMO that she sold. And she's doing it again. So yes, she knows what she is doing. Fleecing shareholders for personal gain. I guess we agree.

If the world thought the JAMA data was good (they didn't) and there were a lot of shorts (there aren't), then there would've been a short squeeze when they released the JAMA article (there wasn't).

As usual, so much stupidity in this mess.

Not a chance of over 1000 compassionate use. Not a chance 100 compassionate use. Probably 10.

The MHRA will piggyback FDA decisions, not the other way around. And the company hasn't secretly submitted a BLA so "readiness" whatever that means is just another ridiculous bunch of crap.

"collaboration". That's from 2016 and hasn't started. It's dead. No mention on University Medical Center (UMC) of the Johannes Gutenberg website except the original PR. Merck gives Keytruda to whomever wants it. That's not a collaboration.

His resume contains ZERO clinical trial submissions which is what is being discussed.

Your typical "throw out some bullshit and hope it's relevant" fails again.

Well you should love the share price tanking. All shills ever do is claim they've only bought the cheapies at .14-17. So you're almost there!

Now all they need to do is spend another 10 years on a P1 or P2 trial, and another 15 on a P3.

Designing, running, and completing trials, an NWBO strength! 😆

That's assuming anyone would give them anything for any stake which is doubtful. Because that stake wouldn't have included Cognate.

I'm writing a book on cults.

Longs 2015: "Soon to be the most well known and respected companies"
Longs 2016: "Soon to be the most well known and respected companies"
Longs 2017: "Soon to be the most well known and respected companies"
Longs 2018: "Soon to be the most well known and respected companies"
.
.
.
Longs 2024: "Soon to be the most well known and respected companies"
.
.
Longs 2030: "Soon to be the most well known and respected companies"

Where did you get your bizarro definition for "soon"?

That's not water, it's DCVax-L. OK, very expensive water.

It's NWBOs problem that they couldn't design a proper trial. They had patient level data for the control arm. The one they designed into the trial! Liau has literally given presentations on pseudoprogression since 2013. When they changed the size of the trial, she should've changed the endpoints before every patient was enrolled and dosed. Yet they waited til the majority were deceased.

If you notice, there are 1 billion + outstanding shares and this did not even trade 500k shares the last two days.

Nobody except those stuck with this POS care about the stock. There's no institutional investors, they skipped submitting a BLA to the FDA because they don't meet the minimum requirements of the FDA for an external control arm, so they submitted an MAA to a largely irrelevant MHRA just to kick the can down the road while LP gets free financing from shareholders to build out a CDMO which she will sell for profit for herself, which she has already done once. And based on history, they're 100 days at least from a decision from the MHRA which will with 99.99% probability be a big fat "no go, amigo".